Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.


TSX:TH - Post by User

Bullboard Posts
Comment by jfm1330on Sep 22, 2020 12:37pm
81 Views
Post# 31597713

RE:RE:Good news coming

RE:RE:Good news coming The important thing is not submission to the FDA, we already know they will do it. The real driver would be a positive answer from FDA.

scarlet1967 wrote: I agree, there was no need to announce  the priminary result shortly before the Q3 in the absence of any previous guidance.
They didn't announce Trogarzo's lunch in Germany to pair it up with NASH news so they have been very strategic releasing news good or bad to maximize the positive reaction.
The market has been very skeptical towards the NASH platform due to the controversial nature of it  thus no added value has been ascribed to the valuation of the company.
I think they will very likely submit the IND for NASH soon and I also believe after more than a year of back and forth negotiations they truly believe the odds to get it approved is very good.
This board has been anxiously discussed the pros and cons of the program but the fact is THTX have been putting together the proposed project with  the support of leading researchers in the field.

palinc2000 wrote: before the Release of the 3 rd Quarter Resuts,
That is why they pre announced on the bad sales numbers to get the bad news out of the way




Bullboard Posts

USER FEEDBACK SURVEY ×

Be the voice that helps shape the content on site!

At Stockhouse, we’re committed to delivering content that matters to you. Your insights are key in shaping our strategy. Take a few minutes to share your feedback and help influence what you see on our site!

The Market Online in partnership with Stockhouse